Announcements Trials
Browse Landscape

Phase

Phase 3 4

Status

Recruiting 3Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Gynecologic 4

Conditions

Carcinoma, Non-Small-Cell Lung 17Prostatic Neoplasms 12Lung Neoplasms 10Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms, Castration-Resistant 4Parkinson Disease 4, Autosomal Dominant Lewy Body 4Endometrial Neoplasms 4Neoplasms 3Breast Neoplasms 3Urinary Bladder Neoplasms 2Stomach Neoplasms 2Salivary Gland Neoplasms 2Oropharyngeal Neoplasms 2Non-Muscle Invasive Bladder Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Lymphoid Interstitial Pneumonia 2Carcinoma, Transitional Cell 2Carcinoma 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Urothelial Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Stage I Prostate Adenocarcinoma AJCC v7 1Solid Tumors 1Small Cell Lung Carcinoma 1Selected Subjects With Advanced Solid Tumors 1

Interventions

Paclitaxel 16pembrolizumab 12Carboplatin 11Specimen Handling 10Magnetic Resonance Spectroscopy 8Biopsy 7Taxes 5Fulvestrant 5Doxorubicin 5olaparib 4dostarlimab 4Nivolumab 4Gemcitabine 4Docetaxel 4Cisplatin 4Bevacizumab 4palbociclib 3X-Rays 3Oxaliplatin 3Leucovorin 3Fluorouracil 3trastuzumab deruxtecan 2ribociclib 2pertuzumab 2ipatasertib 2binimetinib 2abemaciclib 2Trastuzumab 2Surveys and Questionnaires 2Progestins 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Endometrial Neoplasms × Docetaxel × 30 days × Clear all
NCT06952504 2026-05-22

TroFuse-033

Merck Sharp & Dohme LLC

Phase 3 Recruiting
1,123 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

NCT06340568 2026-05-20

Fern-EC-01

BioNTech SE

Phase 3 Recruiting
480 enrolled
Gynecologic

Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

NCT05173987 2026-05-05

KEYNOTE-C93

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
280 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡